Clinical studies recruiting near Flint

Studies with at least one listed site matching this location on the public registry. Each page explains the study in plain language, with locations and study-team contacts. Clinicians: generate a printable list for your patient →

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Wi
Phase 2 · Cancer Hematology Centers - Flint · National Cancer Institute (NCI) · NCT05564390 Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small C
Phase 3 · McLaren Cancer Institute-Flint · NRG Oncology · NCT05624996 Amplitude-Modulated Radiofrequency Electromagnetic Fields (AM RF EMF) in Combination With Fruquintinib in Refractory Met
Phase 2 · Karmanos Cancer Institute at McLaren Flint · Barbara Ann Karmanos Cancer Institute · NCT07130903 Health Impact 360: Advancing Physical, Social, and Mental Health Toward Cardiovascular Disease Prevention in Community S
NA · Hasselbringe Senior Center · University of Michigan · NCT07034352 To Evaluate the Safety and Efficacy of MANP in Subjects With Difficult to Control/ Resistant Hypertension
Phase 2 · Aa Mrc Llc · E-Star BioTech, LLC · NCT06343298 Testing an Enhanced Digital Delivery Model for Inherited Cancer Genetic Testing in Young Adults With Cancer
NA · Cancer Hematology Centers - Flint · Alliance for Clinical Trials in Oncology · NCT07091617 Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
Phase 3 · Genesys Hurley Cancer Institute · NRG Oncology · NCT05946213 Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patient
Phase 2 · McLaren Cancer Institute-Flint · NRG Oncology · NCT06532279 Study of Aritinercept in Patients With Generalized Myasthenia Gravis
Phase 1/Phase 2 · Aurinia Investigational Site · Aurinia Pharmaceuticals Inc. · NCT07596901 Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
Phase 2/Phase 3 · Cancer Hematology Centers - Flint · NRG Oncology · NCT05174169 Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastati
Phase 3 · Genesys Hurley Cancer Institute · Alliance for Clinical Trials in Oncology · NCT06931340 Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-
Phase 3 · McLaren Cancer Institute-Flint · NRG Oncology · NCT06500481 Evaluation of YB-101 for Safety, Tolerability, Pharmacokinetics, and Efficacy in Graves' Disease
Phase 2 · Site 126 · Yarrow Bioscience, Inc. · NCT07682896 ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathol
Phase 3 · Cancer Hematology Centers - Flint · Alliance for Clinical Trials in Oncology · NCT06876714 NV PSR INSPIRE-A Pipeline™ Vantage Post Approval Study
Phase N/A · McLaren Healthcare · Medtronic Neurovascular Clinical Affairs · NCT06604884 Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SL
Phase 3 · Cancer Hematology Centers - Flint · National Cancer Institute (NCI) · NCT04269902 Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and S
Phase 3 · McLaren Cancer Institute-Flint · Canadian Cancer Trials Group · NCT06592924 Reach Out 2: Emergency Department-Initiated Hypertension Mobile Health Intervention Connecting Multiple Health Systems
NA · Hurley Medical Center · Northwestern University · NCT06391073 A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary H
Phase 2/Phase 3 · Elite Clinical Research Center /ID# 256782 · AbbVie · NCT06345339 A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Livi
Phase 2 · Elite Research Center · Novo Nordisk A/S · NCT06717698 An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
Phase 3 · Research Site · AstraZeneca · NCT05952557 Collection of Research Data and Samples From Patients Who Experience Immunotherapy Side Effects
Phase N/A · Cancer Hematology Centers - Flint · Alliance for Clinical Trials in Oncology · NCT04242095 Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carci
Phase 3 · Cancer Hematology Centers - Flint · National Cancer Institute (NCI) · NCT05256225 The Cancer Stage Shifting Initiative: Registry and Biorepository to Research and Address Health Disparities in Cancer Ca
Phase N/A · Life in 3D Health Services · National Minority Quality Forum · NCT07461493 Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidin
Phase 2 · Cancer Hematology Centers - Flint · National Cancer Institute (NCI) · NCT05554393 An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerabilit
Phase 3 · AA Medical Research Center · Novartis Pharmaceuticals · NCT07517263 Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-S
Phase 3 · Cancer Hematology Centers - Flint · National Cancer Institute (NCI) · NCT06498635 Proton Radiation for Unresectable, Borderline Resectable, or Medically Inoperable Carcinoma of the Pancreas
Phase 2 · McLaren Proton Therapy Center · Proton Collaborative Group · NCT02598349 Project: Every Child for Younger Patients With Cancer
Phase N/A · Hurley Medical Center · Children's Oncology Group · NCT02402244 Impact of Sentinel Lymph Node Mapping on Patient Reported Lower Extremity Limb Dysfunction in Stage I Endometrial Cancer
Phase 3 · McLaren Cancer Institute-Flint · NRG Oncology · NCT05646316

Look up another city

Look up another condition